Female with bladder cancer: What and why is there a difference?

Translational Andrology and Urology

Volumn 5, Issue 5, 2016, Pages 668-682

  Marks, Phillip ^a   Soave, Armin ^a   Shariat, Shahrokh F ^b   Fajkovic, Harun ^b   Fisch, Margit ^a   Rink, Michael ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy; Gender; Outcome; Sex; Steroid hormones; Surgery; Survival; Therapy; Urinary bladder neoplasms; Urothelial carcinoma of the bladder (UCB)

Indexed keywords

CARCINOGEN; GLUTATHIONE TRANSFERASE A1; STEROID;

BCG VACCINATION; BLADDER CANCER; CASE REPORT; CYSTECTOMY; DEGRADATION; FEMALE; HUMAN; REVIEW; RISK FACTOR; SMOKING; TRANSITIONAL CELL CARCINOMA;

EID: 85002890171     PISSN: 22234683     EISSN: 22234691     Source Type: Journal    
DOI: 10.21037/tau.2016.03.22     Document Type: Review

References (101)

1. Najari BB, Rink M, Li PS, et al. Sex disparities in cancer mortality: the risks of being a man in the United States. J Urol 2013;189:1470-4
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29
3. Shariat SF, Sfakianos JP, Droller MJ, et al. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010;105:300-8
4. Mungan NA, Kiemeney LA, van Dijck JA, et al. Gender differences in stage distribution of bladder cancer. Urology 2000;55:368-71
5. Scosyrev E, Noyes K, Feng C, et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009;115:68-74
6. Mallin K, David KA, Carroll PR, et al. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol 2011;185:1631-6
7. Kluth LA, Rieken M, Xylinas E, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol 2014;66:913-9
8. Mitra AP, Skinner EC, Schuckman AK, et al. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1, 994 patients. Urol Oncol 2014;32:52.e1-9
9. Messer JC, Shariat SF, Dinney CP, et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014;83:863-7
10. Fajkovic H, Halpern JA, Cha EK, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29:457-63
11. Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 2016;69:300-10
12. Soave A, Dahlem R, Hansen J, et al. Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Eur J Surg Oncol 2015;41:368-77
13. May M, Bastian PJ, Brookman-May S, et al. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol Oncol 2013;31:1141-7
14. Aziz A, Shariat SF, Roghmann F, et al. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU Int 2016;117:272-9
15. Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology 2000;55:876-80
16. Patafio FM, Robert Siemens D, et al. Is there a gender effect in bladder cancer? A population-based study of practice and outcomes. Can Urol Assoc J 2015;9:269-74
17. Daugherty SE, Lacey JV Jr, Pfeiffer RM, et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 2013;133:462-72
18. Bolenz C, Lotan Y, Ashfaq R, et al. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 2009;56:1093-5
19. Gakis G, Stenzl A. Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol 2013;31:1059-64
20. Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004;64:383-8
21. Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 2012;109:1716-26
22. Tilki D, Svatek RS, Karakiewicz PI, et al. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol 2010;183:87-93
23. Henning A, Wehrberger M, Madersbacher S, et al. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int 2013;112:68-73
24. Aziz A, Madersbacher S, Otto W, et al. Comparative analysis of gender-related differences in symptoms and referral patterns prior to initial diagnosis of urothelial carcinoma of the bladder: a prospective cohort study. Urol Int 2015;94:37-44
25. Cohn JA, Vekhter B, Lyttle C, et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer 2014;120:555-61
26. Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer 2010;116:5235-42
27. Cárdenas-Turanzas M, Cooksley C, Kamat AM, et al. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol 2008;40:893-9
28. Siegrist T, Savage C, Shabsigh A, et al. Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology. Urol Oncol 2010;28:112-7
29. Liberman D, Lughezzani G, Sun M, et al. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology 2011;77:660-6
30. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414-22; discussion 22
31. Puente D, Malats N, Cecchini L, et al. Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol 2003;43:53-62
32. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1001
33. Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 2010;106:357-61
34. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol 2012;62:118-25
35. Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 2013;119:3219-27
36. Kluth LA, Fajkovic H, Xylinas E, et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 2013;31:1029-36
37. Gontero P, Sylvester R, Pisano F, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015;67:74-82
38. Tilki D, Reich O, Svatek RS, et al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol 2010;183:1757-63
39. May M, Stief C, Brookman-May S, et al. Gender-dependent cancer-specific survival following radical cystectomy. World J Urol 2012;30:707-13
40. Otto W, May M, Fritsche HM, et al. Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med 2012;9:481-9
41. Kaushik D, Frank I, Eisenberg MS, et al. Gender-specific survival following radical cystectomy for pT4 bladder cancer. World J Urol 2014;32:1433-9
42. Liberman D, Alasker A, Sun M, et al. Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study. BJU Int 2011;107:905-11
43. Patel MI, Bang A, Gillett D, et al. Poor survival of females with bladder cancer is limited to those aged 70 years or over: a population-wide linkage study, New South Wales, Australia. Cancer Med 2015;4:1145-52
44. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778-92
45. Haines L, Bamias A, Krege S, et al. The impact of gender on outcomes in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer 2013;11:346-52
46. Pal SK, Lin YI, Yuh B, et al. Conditional Survival in de novo Metastatic Urothelial Carcinoma. PLoS One 2015;10:e0136622
47. Apolo AB, Ostrovnaya I, Halabi S, et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst 2013;105:499-503
48. Galsky MD, Moshier E, Krege S, et al. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol 2014;32:48 e1-8
49. Donsky H, Coyle S, Scosyrev E, et al. Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urol Oncol 2014;32:40.e23-31
50. Schmid M, Shariat SF, Soave A, et al. Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer. Curr Urol Rep 2014;15:409
51. Rink M, Chun FK, Chromecki TF, et al. Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies. Urologe A 2012;51:820-8
52. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004;22:86-92
53. Saez S, Martin PM. Evidence of estrogen receptors in the trigone area of human urinary bladder. J Steroid Biochem 1981;15:317-20
54. Schilling D, Horstmann M, Nagele U, et al. Cystectomy in women. BJU Int 2008;102:1289-95
55. Maralani S, Wood DP Jr, Grignon D, et al. Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study. Urology 1997;50:537-41
56. Bassett JC, Alvarez J, Koyama T, et al. Gender, race, and variation in the evaluation of microscopic hematuria among Medicare beneficiaries. J Gen Intern Med 2015;30:440-7
57. Casey JT, Berkowitz LL, Cashy J, et al. A protocol based, electronic medical record enabled care coordination system improves the timeliness and efficiency of care for patients with hematuria. J Urol 2013;190:212-7
58. Snyder C, Harlan L, Knopf K, et al. Patterns of care for the treatment of bladder cancer. J Urol 2003;169:1697-701
59. Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003;170:1765-71
60. Schmid M, Rink M, Traumann M, et al. Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer? Ann Surg Oncol 2015;22:1032-42
61. Herkommer K, Hofer C, Gschwend JE, et al. Gender and body mass index as risk factors for bladder perforation during primary transurethral resection of bladder tumors. J Urol 2012;187:1566-70
62. Valerio M, Cerantola Y, Fritschi U, et al. Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study. Can Urol Assoc J 2014;8:E600-4
63. Lavallée LT, Schramm D, Witiuk K, et al. Peri-operative morbidity associated with radical cystectomy in a multicenter database of community and academic hospitals. PLoS One 2014;9:e111281
64. Gierth M, Mayr R, Aziz A, et al. Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy. J Cancer Res Clin Oncol 2015;141:1819-26
65. Schiffmann J, Gandaglia G, Larcher A, et al. Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol 2014;40:1738-45
66. Roghmann F, Trinh QD, Braun K, et al. Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy. Int J Urol 2014;21:143-9
67. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65:742-54
68. Rink M, Crivelli JJ, Shariat SF, et al. Smoking and bladder cancer: a systematic review of risk and outcomes. Eur Urol 2015;1:17-27
69. Jiang X, Yuan JM, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res 2007;67:7540-5
70. Simonis K, Shariat SF, Rink M. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Curr Opin Urol 2014;24:492-9
71. Rink M, Zabor EC, Furberg H, et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol 2013;64:456-64
72. Marsit CJ, Houseman EA, Schned AR, et al. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 2007;28:1745-51
73. Rink M, Furberg H, Zabor EC, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 2013;63:724-32
74. Rink M, Xylinas E, Babjuk M, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol 2012;188:2120-7
75. Rieken M, Xylinas E, Kluth L, et al. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol 2014;65:201-9
76. Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15, 215 patients. J Clin Oncol 2015;33:643-50
77. Boström PJ, Alkhateeb S, Trottier G, et al. Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU Int 2012;109:70-6
78. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311:183-92
79. Amos A, Greaves L, Nichter M, et al. Women and tobacco: a call for including gender in tobacco control research, policy and practice. Tob Control 2012;21:236-43
80. Hemelt M, Yamamoto H, Cheng KK, et al. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer 2009;124:412-9
81. Krabbe LM, Svatek RS, Shariat SF, et al. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. Urol Oncol 2015;33:65.e19-25
82. Cumberbatch MG, Cox A, Teare D, et al. Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2015;1:1282-90
83. Koutros S, Silverman DT, Baris D, et al. Hair dye use and risk of bladder cancer in the New England bladder cancer study. Int J Cancer 2011;129:2894-904
84. Botelho MC, Figueiredo J, Alves H. Bladder cancer and urinary Schistosomiasis in Angola. J Nephrol Res 2015;1:22-4
85. Michaud DS, Platz EA, Giovannucci E. Gonorrhoea and male bladder cancer in a prospective study. Br J Cancer 2007;96:169-71
86. Gutiérrez J, Jiménez A, de Dios Luna J, et al. Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus. J Urol 2006;176:2474-81; discussion 81
87. Shigehara K, Sasagawa T, Namiki M. Human papillomavirus infection and pathogenesis in urothelial cells: a mini-review. J Infect Chemother 2014;20:741-7
88. Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009;91:4-15; discussion 1-3
89. Nilsson S, Ullén A. Chemotherapy-induced bladder cancer. Scand J Urol Nephrol Suppl 2008;(218):89-92
90. Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013;31:287-304
91. Wu H, Wang X, Zhang L, et al. Association between N-acetyltransferase 2 polymorphism and bladder cancer risk: results from studies of the past decade and a meta-analysis. Clin Genitourin Cancer 2016;14:122-9
92. McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006;163:236-44
93. Cantwell MM, Lacey JV Jr, Schairer C, et al. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int J Cancer 2006;119:2398-401
94. Lombard AP, Mudryj M. The emerging role of the androgen receptor in bladder cancer. Endocr Relat Cancer 2015;22:R265-77
95. Boorjian SA, Heemers HV, Frank I, et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 2009;16:123-37
96. Izumi K, Zheng Y, Hsu JW, et al. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog 2013;52:94-102
97. Ren B, Li W, Yang Y, et al. The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis. World J Surg Oncol 2014;12:55
98. Li Y, Zheng Y, Izumi K, et al. Androgen activates beta-catenin signaling in bladder cancer cells. Endocr Relat Cancer 2013;20:293-304
99. Zhao J, Xu W, Zhang Z, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol 2015;47:87-94
100. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-alpha and-beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-6
101. George SK, Tovar-Sepulveda V, Shen SS, et al. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 2013;6:244-55